MAPK3 and cancer: To test whether IL-6, one of the main SASP factors, contributes to the cancer promoting effect of the SASP and the ERK1/2 pathway activation, we added recombinant IL-6 to CMns-treated MCF7 cells and an anti-IL-6 antibody to CMsn-treated MCF7 cells.